Brings proven leadership and a track record of success raising capital, scaling companies, and executing drug development programs Barbara S. Fox , Ph.D.
, named chair of Alphina's board of directors NEW HAVEN, Conn. , Oct. 23, 2024 /PRNewswire/ -- Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of solid tumor indications, today announced that it has appointed Nick Galli as chief executive officer and a member of the board of directors.
Mr. Galli brings nearly twenty years of private and public pharmaceutical and biotechnology industry experience with a focus on strategy, company building, and business development. As an executive, he has helped biotech companies raise over $450 million in equity and upfront non-dilutive capital.
In conjunction with Mr. Galli's appointment, Barbara S. Fox , Ph.
D., who had been serving as Alphina's interim CEO, will become chair of the company's board of directors. "We are excited to welcome Nick to Alphina and thrilled that Barbara will continue to support the company in the role of board chair.
Their combined experience and track records of success will help ensure the continued efficient advancement of the company's best-in-class NAMPT inhibitor program, with the goal of entering the clinic in the next 18 months," said Colleen Cuffaro , Ph.D., a member of Alphina's board and a partner at Canaan Partners.
Alphina's approach to NAMPT inhibition leverages several novel insigh.
